This technology introduces a novel approach to cancer treatment by targeting Protein Phosphatase 5 (PP5) to regulate apoptosis and inhibit tumor growth, particularly in clear cell renal cell carcinoma (ccRCC).
Background: Cancer cells often evade programmed cell death, allowing tumors to grow unchecked. In clear cell renal cell carcinoma, dysregulation of key signaling pathways disrupts apoptosis, contributing to cancer progression. Protein Phosphatase 5 (PP5), a serine/threonine phosphatase, has been found to interact with proteins involved in the extrinsic apoptotic pathway, modulating cell survival. Understanding and manipulating this mechanism opens promising avenues for cancer therapy.
Technology Overview: The invention focuses on PP5’s critical role in cancer cell survival by dephosphorylating and inactivating proteins that trigger apoptosis, such as caspase-8, FADD, and RIPK1. PP5 maintains the integrity of Complex II, a molecular assembly essential for initiating programmed cell death. The technology introduces a specific inhibitor named P-53, which blocks substrate binding to PP5, thereby preventing its anti-apoptotic action. Inhibition of PP5 by P-53 leads to increased apoptotic activity in VHL-null ccRCC cells, restoring the natural pathway for cell death and suppressing tumor growth. This targeted therapy offers a precise mechanism to selectively induce cancer cell apoptosis without affecting healthy cells, making it a potentially effective treatment for renal cancer and other malignancies with similar pathways.
https://suny.technologypublisher.com/files/sites/adobestock_1041788413.jpeg Photo for reference only, not a depiction of the invention.
Advantages: • Selective targeting of PP5 provides a focused therapeutic approach that minimizes damage to normal cells. • Restores the natural apoptotic process in cancer cells, overcoming resistance to cell death. • Potentially effective against clear cell renal cell carcinoma, especially VHL-null tumor types which are typically difficult to treat. • Novel mechanism of action that differs from conventional chemotherapies, offering new treatment options. • Supported by a robust scientific understanding of PP5’s role in apoptosis and cancer signaling pathways.
Applications: • Treatment of clear cell renal cell carcinoma through targeted apoptosis induction. • Potential application in other cancers where PP5-mediated dephosphorylation disrupts apoptotic pathways. • Development of new cancer therapeutics based on PP5 inhibition as a mechanism to trigger tumor cell death. • Research tool for studying PP5’s role in cancer biology and apoptotic regulation.
Intellectual Property Summary: Patent application filed: 18/873,996 https://patents.google.com/patent/US20250360108A1/en
Stage of Development: TRL 3 – Experimental Proof of Concept
Licensing Status: This technology is available for licensing.